A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network)

Critical Reviews in Oncology/Hematology

Volumn 91, Issue 2, 2014, Pages 142-158

  Cerda, Thomas ^a,b   Sun, Xu Shan ^a,b   Vignot, Stéphane ^c   Marcy, Pierre Yves ^d   Baujat, Bertrand ^e   Baglin, Anne Catherine ^f   Ali, Ali Mohamed ^g   Testelin, Sylvie ^h   Reyt, Emile ⁱ   Janot, Francois ^f   Thariat, Juliette ^d  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b Department of Oncology CHBM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d CENTRE ANTOINE LACASSAGNE   (France)

^e HÔPITAL TENON   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g Sohag University   (Egypt)

^h AMIENS UNIVERSITY HOSPITAL   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Adenoid cystic carcinoma; Cancer; Chemotherapy; Histology; Radiation therapy; Rare; Salivary gland; Survival

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IMATINIB; IRINOTECAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PIRARUBICIN; TRASTUZUMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

ACINAR CELL CARCINOMA; ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ANEMIA; CANCER RADIOTHERAPY; CARCINOMA; CARCINOMA EXPLEOMORPHIC ADENOMA; DERMATITIS; DRUG RESPONSE; DYSPHAGIA; ESOPHAGITIS; FEBRILE NEUTROPENIA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; MALIGNANT MIXED TUMOR; MIXED TUMOR; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYOEPITHELIAL CARCINOMA; NAUSEA; NEUTROPENIA; ONCOCYTIC CARCINOMA; PAIN; PLEOMORPHIC ADENOMA; PNEUMONIA; POORLY DIFFERENTIATED CARCINOMA; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; RASH; REVIEW; SALIVARY GLAND CARCINOMA; SALIVARY GLAND TUMOR; SOFT TISSUE DISEASE; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TRISMUS; UNDIFFERENTIATED CARCINOMA; VOMITING; XEROSTOMIA; CHEMORADIOTHERAPY; DRUG EFFECTS; PATHOLOGY; PROCEDURES; SALIVARY GLAND; SALIVARY GLAND NEOPLASMS; SURVIVAL;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; HUMANS; RADIATION-SENSITIZING AGENTS; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; SURVIVAL ANALYSIS;

EID: 84903455596     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.02.002     Document Type: Review

References (77)

1. Terhaard C.H.J., Lubsen H., Van der Tweel I., et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004, 26:681-692. [discussion 692-693].
2. Weinreb I. Translocation-associated salivary gland tumors: a review and update. Adv Anat Pathol 2013, 20:367-377.
3. Vander Poorten V.L.M., Hart A.A.M., van der Laan B.F.A.M., et al. Prognostic index for patients with parotid carcinoma: external validation using the nationwide 1985-1994 Dutch Head and Neck Oncology Cooperative Group database. Cancer 2003, 97:1453-1463.
4. Nance M.A., Seethala R.R., Wang Y., et al. Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer 2008, 113:2082-2089.
5. Seethala R.R. Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol 2011, 18:29-45.
6. Seethala R.R. An update on grading of salivary gland carcinomas. Head Neck Pathol 2009, 3:69-77.
7. Hocwald E., Korkmaz H., Yoo G.H., et al. Prognostic factors in major salivary gland cancer. Laryngoscope 2001, 111:1434-1439.
8. Gomez D.R., Hoppe B.S., Wolden S.L., et al. Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: a recent experience. Int J Radiat Oncol Biol Phys 2008, 70:1365-1372.
9. Chen A.M., Bucci M.K., Quivey J.M., Garcia J., Eisele D.W., Fu K.K. Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys 2006, 66:1044-1050.
10. Borthne A., Kjellevold K., Kaalhus O., Vermund H. Salivary gland malignant neoplasms: treatment and prognosis. Int J Radiat Oncol Biol Phys 1986, 12:747-754.
11. Harrison L.B., Armstrong J.G., Spiro R.H., Fass D.E., Strong E.W. Postoperative radiation therapy for major salivary gland malignancies. J Surg Oncol 1990, 45:52-55.
12. Guzzo M., Locati L.D., Prott F.J., Gatta G., McGurk M., Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol 2010, 74:134-148.
13. Armstrong J.G., Harrison L.B., Spiro R.H., Fass D.E., Strong E.W., Fuks Z.Y. Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 1990, 116:290-293.
14. Salgado L.R., Spratt D.E., Riaz N., et al. Radiation therapy in the treatment of minor salivary gland tumors. Am J Clin Oncol 2013, [Epub ahead of print].
15. Chung M.P., Tang C., Chan C., et al. Radiotherapy for nonadenoid cystic carcinomas of major salivary glands. Am J Otolaryngol 2013, 34:425-430.
16. Shen C., Xu T., Huang C., Hu C., He S. Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck. Oral Oncol 2012, 48:445-449.
17. Al-Mamgani A., van Rooij P., Sewnaik A., Tans L., Hardillo J.A.U. Adenoid cystic carcinoma of parotid gland treated with surgery and radiotherapy: long-term outcomes, QoL assessment and review of the literature. Oral Oncol 2012, 48:278-283.
18. Dubergé T., Bénézery K., Resbeut M., et al. Adenoid cystic carcinoma of the head and neck: a retrospective series of 169 cases. Cancer Radiothér 2012, 16:247-256.
19. Li Q., Zhang X.-R., Liu X.-K., et al. Long-term treatment outcome of minor salivary gland carcinoma of the hard palate. Oral Oncol 2012, 48:456-462.
20. Noh J.M., Ahn Y.C., Nam H., et al. Treatment results of major salivary gland cancer by surgery with or without postoperative radiation therapy. Clin Exp Otorhinolaryngol 2010, 3:96-101.
21. Bhide S.A., Miah A., Barbachano Y., Harrington K.J., Newbold K., Nutting C.M. Radical radiotherapy for treatment of malignant parotid tumours: a single centre experience 1995-2005. Br J Oral Maxillofac Surg 2009, 47:284-289.
22. Chen A.M., Garcia J., Bucci M.K., Quivey J.M., Eisele D.W. The role of postoperative radiation therapy in carcinoma ex pleomorphic adenoma of the parotid gland. Int J Radiat Oncol Biol Phys 2007, 67:138-143.
23. Koul R., Dubey A., Butler J., Cooke A.L., Abdoh A., Nason R. Prognostic factors depicting disease-specific survival in parotid-gland tumors. Int J Radiat Oncol Biol Phys 2007, 68:714-718.
24. Mendenhall W.M., Morris C.G., Amdur R.J., Werning J.W., Villaret D.B. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 2005, 103:2544-2550.
25. Pohar S., Gay H., Rosenbaum P., et al. Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. Int J Radiat Oncol Biol Phys 2005, 61:112-118.
26. Schulz-Ertner D., Nikoghosyan A., Didinger B., et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 2005, 104:338-344.
27. Bell R.B., Dierks E.J., Homer L., Potter B.E. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005, 63:917-928.
28. Lima R.A., Tavares M.R., Dias F.L., et al. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg 2005, 133:702-708.
29. Terhaard C.H.J., Lubsen H., Rasch C.R.N., et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005, 61:103-111.
30. Zbären P., Schüpbach J., Nuyens M., Stauffer E., Greiner R., Häusler R. Carcinoma of the parotid gland. Am J Surg 2003, 186:57-62.
31. Storey M.R., Garden A.S., Morrison W.H., Eicher S.A., Schechter N.R., Ang K.K. Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys 2001, 51:952-958.
32. Kirkbride P., Liu F.F., O'Sullivan B., et al. Outcome of curative management of malignant tumours of the parotid gland. J Otolaryngol 2001, 30:271-279.
33. Douglas J.G., Laramore G.E., Austin-Seymour M., Koh W., Stelzer K., Griffin T.W. Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 2000, 46:551-557.
34. Mahmood U., Koshy M., Goloubeva O., Suntharalingam M. Adjuvant radiation therapy for high-grade and/or locally advanced major salivary gland tumors. Arch Otolaryngol Head Neck Surg 2011, 137:1025-1030.
35. Rosenberg L., Weissler M., Hayes D.N., et al. Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies. Head Neck 2012, 34:872-876.
36. Pederson A.W., Salama J.K., Haraf D.J., et al. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol 2011, 3:31.
37. Schoenfeld J.D., Sher D.J., Norris C.M., et al. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2012, 82:308-314.
38. Tanvetyanon T., Qin D., Padhya T., et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 2009, 135:687-692.
39. Katori H., Tsukuda M. Concurrent chemoradiotherapy with cyclophosphamide, pirarubicin, and cisplatin for patients with locally advanced salivary gland carcinoma. Acta Otolaryngol 2006, 126:1309-1314.
40. Maruya S., Namba A., Matsubara A., et al. Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol 2006, 11:403-406.
41. Hitre E., Budai B., Takácsi-Nagy Z., et al. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 2013, 109:1117-1122.
42. Karam S.D., Snider J.W., Wang H., et al. Reirradiation of recurrent salivary gland malignancies with fractionated stereotactic body radiation therapy. J Radiat Oncol 2012, 1:147-153.
43. Samant S., van den Brekel M.W., Kies M.S., et al. Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head Neck 2012, 34:1263-1268.
44. Jensen A.D., Krauss J., Weichert W., Debus J., Münter M.W. RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab. Radiat Oncol 2010, 5:102.
45. Haddad R.I., Posner M.R., Busse P.M., et al. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol 2006, 29:153-157.
46. Airoldi M., Gabriele A.M., Gabriele P., et al. Concomitant chemoradiotherapy followed by adjuvant chemotherapy in parotid gland undifferentiated carcinoma. Tumori 2001, 87:14-17.
47. Pederson A.W., Haraf D.J., Blair E.A., et al. Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol 2010, 95:308-311.
48. Bouyon A., Hans S., Durdux C., Housset M. Postoperative treatment of malignant tumors of the parotid gland: radiotherapy, concomitant chemotherapy and radiation therapy?. Cancer Radiothér 2007, 11:465-475.
49. Battermann J.J., Breur K., Hart G.A., van Peperzeel H.A. Observations on pulmonary metastases in patients after single doses and multiple fractions of fast neutrons and cobalt-60 gamma rays. Eur J Cancer 1981, 17:539-548.
50. Griffin T.W., Pajak T.F., Laramore G.E., et al. Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study. Int J Radiat Oncol Biol Phys 1988, 15:1085-1090.
51. Catterall M., Errington R.D. The implications of improved treatment of malignant salivary gland tumors by fast neutron radiotherapy. Int J Radiat Oncol Biol Phys 1987, 13:1313-1318.
52. Saroja K.R., Mansell J., Hendrickson F.R., Cohen L., Lennox A. An update on malignant salivary gland tumors treated with neutrons at Fermilab. Int J Radiat Oncol Biol Phys 1987, 13:1319-1325.
53. Buchholz T.A., Laramore G.E., Griffin B.R., Koh W.J., Griffin T.W. The role of fast neutron radiation therapy in the management of advanced salivary gland malignant neoplasms. Cancer 1992, 69:2779-2788.
54. Stannard C., Vernimmen F., Carrara H., et al. Malignant salivary gland tumours: can fast neutron therapy results point the way to carbon ion therapy?. Radiother Oncol 2013, 109(2):262-268.
55. Lawrence T.S., Eisbruch A., Shewach D.S. Gemcitabine-mediated radiosensitization. Semin Oncol 1997, 24. S7-24-S7-28.
56. Sartor C.I. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin Oncol 2000, 27:15-20. [discussion 92-100].
57. Airoldi M., Cortesina G., Giordano C., et al. Update and perspectives on non-surgical treatment of salivary gland malignancies. Acta Otorhinolaryngol Ital 2003, 23:368-376.
58. Gilbert J., Li Y., Pinto H.A., et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 2006, 28:197-204.
59. Van Herpen C.M.L., Locati L.D., Buter J., et al. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer 2008, 44:2542-2545.
60. Airoldi M., Pedani F., Succo G., et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 2001, 91:541-547.
61. Lagha A., Chraiet N., Ayadi M., et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol 2012, 4:19.
62. Suen J.Y., Johns M.E. Chemotherapy for salivary gland cancer. Laryngoscope 1982, 92:235-239.
63. Kaplan M.J., Johns M.E., Cantrell R.W. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 1986, 95:165-170.
64. Laurie S.A., Ho A.L., Fury M.G., Sherman E., Pfister D.G. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 2011, 12:815-824.
65. Lawrence T.S., Blackstock A.W., McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003, 13:13-21.
66. Lagha A., Chraiet N., Ayadi M., et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers. Oral Oncol 2012, 48:948-957.
67. Adelstein D.J., Koyfman S.A., El-Naggar A.K., Hanna E.Y. Biology and management of salivary gland cancers. Semin Radiat Oncol 2012, 22:245-253.
68. Boukheris H., Curtis R.E., Land C.E., Dores G.M. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomark Prev 2009, 18:2899-2906.
69. Bumpous J. Metastatic cutaneous squamous cell carcinoma to the parotid and cervical lymph nodes: treatment and outcomes. Curr Opin Otolaryngol Head Neck Surg 2009, 17:122-125.
70. Dahse R., Kromeyer-Hauschild K., Berndt A., Kosmehl H. No incidence of BRAF mutations in salivary gland carcinomas - implications for anti-EGFR therapies. J Biomed Biotechnol 2009, 2009:501736.
71. Milanovic D., Jeremic B., Kayser G., Rischke H.C., Pfeiffer J., Henke A. Relapsing high grade mucoepidermoid carcinoma. Long-lasting complete response following reirradiation and EGFR blockade. Strahlenther Onkol 2012, 188:518-522.
72. Milanović D., Jeremić B., Grosu A.L., Rücker G., Henke M. Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer: final results from a single institution. Strahlenther Onkol 2013, 189:842-848.
73. Agulnik M., Cohen E.W.E., Cohen R.B., et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007, 25:3978-3984.
74. Münter M.W., Schulz-Ertner D., Hof H., et al. Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the treatment of incompletely and completely resected adenoid cystic carcinomas of the head and neck: initial clinical results and toxicity of treatment. Radiat Oncol 2006, 1:17.
75. Kasibhatla M., Kirkpatrick J.P., Brizel D.M. How much radiation is the chemotherapy worth in advanced head and neck cancer?. Int J Radiat Oncol Biol Phys 2007, 68:1491-1495.
76. Fowler J.F. Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? (Int J Radiat Oncol Biol Phys 2007;68:1491-1495). Int J Radiat Oncol Biol Phys 2008, 71:326-329.
77. Cortesina G., Airoldi M., Palonta F. Current role of chemotherapy in exclusive and integrated treatment of malignant tumours of salivary glands. Acta Otorhinolaryngol Ital 2005, 25:179-181.